Mottl, A., Scott, C., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., … CONFIDENCE Trial Investigators. (2025). Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. https://doi.org/10.1681/ASN.0000000928

Mottl, Amy, Charlie Scott, Jennifer B. Green, Hiddo J. L. Heerspink, Johannes F. E. Mann, Janet B. McGill, Masaomi Nangaku, et al. “Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.” J Am Soc Nephrol, November 6, 2025. https://doi.org/10.1681/ASN.0000000928.

Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, et al. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2025 Nov 6;

Mottl, Amy, et al. “Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.” J Am Soc Nephrol, Nov. 2025. Pubmed, doi:10.1681/ASN.0000000928.

Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R, CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2025 Nov 6;